Tilray Brands (NASDAQ:TLRY), a global player in the medical cannabis sector, saw its shares rise by 27.54% on Tuesday, closing at $13.94. Trading volume peaked at 46.8 million shares, which is about 525% more than the three-month average of 8.9 million shares.
This surge aligns with a broader uptick in the cannabis industry following President Trump’s remarks about potentially reclassifying marijuana. Investors are increasingly attuned to possible U.S. policy shifts that could significantly influence industry growth, while the S&P 500 (SNPINDEX:^GSPC) dipped slightly by 0.26%, hitting 6,799. In contrast, the Nasdaq Composite (NASDAQINDEX:^IXIC) rose a bit, gaining 0.23% to reach 23,111.
Other cannabis companies, like Canopy Growth (NASDAQ:CGC) and Kronos Group (NASDAQ:KRON), experienced price increases of 10.24% and 3.61%, respectively. This demonstrates the sector’s optimism regarding potential changes in U.S. cannabis regulations.
With the latest gains, Tilray’s stock is nearing a two-month high. Many investors are feeling more confident in light of Trump’s statement about “strongly” considering marijuana reclassification from Schedule I to Schedule III. This shift has many jumping at the opportunity to invest in cannabis stocks.
An executive order reclassifying marijuana would place it at a similar level as Tylenol with codeine and other regulated drugs, thereby broadening Tilray’s market. If successful, it might become the first federally approved medical cannabis product. Yet, it’s important to note that discussions about reclassification aren’t new; however, investor sentiment seems convinced that change is finally on the horizon.
